Effects of cellular pharmacology on drug distribution in tissues  by Rippley, R.K. & Stokes, C.L.
Biophysical Journal Volume 69 September 1995 825-839
Effects of Cellular Pharmacology on Drug Distribution in Tissues
Ronda K. Rippley and Cynthia L. Stokes
Department of Chemical Engineering, University of Houston, Houston, Texas 77204 USA
ABSTRACT The efficacy of targeted therapeutics such as immunotoxins is directly related to both the extent of distribution
achievable and the degree of drug internalization by individual cells in the tissue of interest. The factors that influence the
tissue distribution of such drugs include drug transport; receptor/drug binding; and cellular pharmacology, the processing
and routing of the drug within cells. To examine the importance of cellular pharmacology, previously treated only superficially,
we have developed a mathematical model for drug transport in tissues that includes drug and receptor internalization,
recycling, and degradation, as well as drug diffusion in the extracellular space and binding to cell surface receptors. We have
applied this "cellular pharmacology model" to a model drug/cell system, specifically, transferrin and the well-defined
transferrin cycle in CHO cells. We compare simulation results to models with extracellular diffusion only or diffusion with
binding to cell surface receptors and present a parameter sensitivity analysis. The comparison of models illustrates that
inclusion of intracellular trafficking significantly increases the total transferrin concentration throughout much of the tissue
while decreasing the penetration depth. Increasing receptor affinity or tissue receptor density reduces permeation of
extracellular drug while increasing the peak value of the intracellular drug concentration, resulting in "internal trapping" of
transferrin near the source; this could account for heterogeneity of drug distributions observed in experimental systems. Other
results indicate that the degree of drug internalization is not predicted by the total drug profile. Hence, when intracellular drug
is required for a therapeutic effect, the optimal treatment may not result from conditions that produce the maximal total drug
distribution. Examination of models that include cellular pharmacology may help guide rational drug design and provide useful
information for whole body pharmacokinetic studies.
INTRODUCTION
Accurate delivery of therapeutic drugs to the appropriate
tissues is necessary to maximize efficacy of treatment and
minimize harmful side effects in non-diseased tissues. The
advent of monoclonal antibody technology motivated the
idea that tissues might be selectively targeted by macromo-
lecular drugs, a new approach to disease detection and
treatment. Targeted drug delivery strategies have numerous
potential applications, including cancer detection and treat-
ment (LoBuglio and Saleh, 1992), anti-growth factor recep-
tor therapy (Mulshine et al., 1992), and gene therapy (Chen
et al., 1994). However, physiological complications can
preclude the in vivo efficacy of therapeutics that are suc-
cessful in vitro. Often, a drug is ineffective in vivo because
it reaches the target tissue in insufficient quantities for a
number of reasons (Jain, 1989; Weinstein et al., 1987;
Epstein and Khawli, 1991). Drug may be degraded before
reaching the diseased tissue, or drug transport across capil-
laries into surrounding tissue may be restricted (Jain, 1989).
Drug that does access the tissue may be degraded by cells
nearest the blood vessels before it can reach interior target
cells (Jain, 1994). In addition, transport of macromolecular
drugs in tumors may be impeded by interstitial fluid pres-
sure gradients (Boucher et al., 1990) or by specific binding
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to surface receptors on cells near blood vessels (Juweid et
al., 1992).
In this work, we are interested in the processes that
govern the distribution of drug within a tissue once the drug
reaches that tissue. Factors that determine drug access to
and specificity for the desired target tissue include physi-
cochemical factors and cellular pharmacology (Jain, 1989;
van Osdol et al., 1991; Epstein and Khawli, 1991; Stein and
Cheng, 1993). The diffusive and convective transport of
drug throughout the target tissue is governed by vascular
permeability, tissue heterogeneity, convection of interstitial
fluid, drug diffusivity, and interstitial fluid pressure. The
cellular pharmacology, which includes drug/receptor bind-
ing at the cell surface, internalization, and intracellular
routing, determines the drug interaction with the tissue cells.
Simple delivery of drug to a tissue may be inadequate for
therapy, however, because the actions of many drugs such
as immunotoxins, hormonotoxins, and oligonucleotides re-
quire intracellular access (Olsnes et al., 1989; Stein and
Cheng, 1993, Preijers et al., 1988). Consequently, several
current approaches to drug design attempt to achieve entry
into cells by exploiting receptor-mediated processes. Mono-
clonal antibody/drug conjugates can be directed against
disease-specific cell surface receptors, e.g., tumor markers
such as melanoma-associated antigen (LoBuglio and Saleh,
1992). Receptors for growth factors, transferrin, and low
density lipoprotein are often overexpressed in malignant
tissues (Vitetta et al., 1993; Thorstensen and Romslo, 1993;
Firestone, 1994) and hence make good targets for high
affinity drugs. To take advantage of receptors for molecules
that are required for cell growth, some strategies involve
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conjugates of toxins to anti-transferrin receptor antibodies
(Martell et al., 1993), anti-growth factor receptor antibodies
(Kim et al., 1993; Hirota et al., 1989) or natural receptor
ligands such as hormonal growth factors (Vitetta et al.,
1993; Schwartz et al., 1987) and low density lipoprotein
(Firestone, 1994). Unfortunately, a further complication is
that internalization of drug may be necessary but insuffi-
cient for efficacy. For instance, cytotoxicity may be depen-
dent on the rates of specific cellular drug processing and
routing steps (Akhtar and Juliano, 1992; Wargalla and
Reisfeld, 1989; Byers et al., 1991; May et al., 1991).
The large number of transport and pharmacological pa-
rameters that influence drug distribution in a tissue and the
difficulty of measuring drug distributions in animal systems
encumber in vivo study of targeted drug delivery (Leichner
et al., 1990). The complexity of the problem has attracted
mathematical analyses. Previous models have examined
targeted drug delivery using the paradigm of monoclonal
antibody uptake by a tumor. Compartmental pharmacoki-
netic models describe average drug concentrations in the
plasma, target tissue, and organs such as the liver and
kidneys (e.g., Sung et al., 1992; Thomas et al., 1989). These
models lump together such processes as reversible drug
binding and drug endocytosis and metabolism into one
process, described by a single rate parameter. A major
limitation of lumped parameter models, the lack of spatial
drug distribution information, is rectified by distributed
parameter models (e.g., Baxter and Jain, 1991; McFadden
and Kwok, 1988). The latter provide drug concentration
profiles in the target tissue and have been used to study the
effects of interstitial fluid flow and pressure on drug distri-
bution (Baxter and Jain, 1991). Other models have com-
bined the salient aspects of global compartmental pharma-
cokinetics and distributed parameter models to consider the
impact of treatment protocols, capillary permeability, lym-
phatic efflux, and other binding and transport parameters
(e.g., van Osdol et al., 1991, 1993; Baxter et al., 1992). The
cellular internalization and trafficking of drug, however,
were accounted for by a single metabolism rate constant.
In this paper, we describe a mathematical model that
explicitly includes the cellular pharmacology to explore its
effects on drug distribution in a model tissue. The model
combines drug transport and specific, saturable binding
processes with descriptions of drug and receptor internal-
ization and trafficking. Our goal is to predict whether cel-
lular pharmacology has a significant impact on drug trans-
port and distribution in tissues and, if so, what cellular
processes might be targeted in rational design of therapeu-
tics to maximize efficacy. We have used the model to
examine the impact of cellular pharmacology on the distri-
bution of transferrin in a tissue expressing the transferrin
receptor. We chose transferrin and its receptor as the model
system because this receptor is often overexpressed in ma-
lignant tissues (Thorstensen and Romslo, 1993) and there-
fore has diagnostic and therapeutic potential. In fact, the
transferrin receptor has been a target for immunotoxin ther-
the blood-brain barrier (Yoshikawa and Pardridge, 1992),
and gene therapy (Citro et al., 1992; Cotten et al., 1990). In
addition, the endocytic cycle of transferrin via the trans-
ferrin receptor is well characterized in a number of cell lines
(Ciechanover et al., 1983; Cain et al., 1991; Klausner et al.,
1983), and so the binding, internalization and recycle rate
constants are available for use in the model. Our results
predict that cellular pharmacology strongly affects the dis-
tribution of transferrin in tissue. One important observation
is that the total tissue concentration of transferrin (extracel-
lular plus cell-associated) does not necessarily predict in-
tracellular transferrin levels, demonstrating that total drug
concentration may not be a sufficient indicator of drug
efficacy. In addition, increasing receptor density or recep-
tor/transferrin affinity impedes transferrin penetration in the
tissue and gives rise to an "internal trapping" of transferrin
near the source. This may be the actual cause of the exper-
imentally observed "binding site barrier" (Fujimori et al.,
1989) for ligands that are internalized.
MATHEMATICAL MODEL AND METHODS
Cellular pharmacology model
We have developed a cellular pharmacology model that
describes the local pharmacokinetics of a macromolecular
drug in tissue. In this work we apply the model to a specific
cell type and receptor/ligand system relevant to targeted
drug delivery. We include extracellular diffusive drug trans-
port, specific reversible binding of drug to cell surface
receptors, and a detailed consideration of receptor-mediated
endocytosis and trafficking of drug. We neglect contribu-
tions of convection in this treatment, as our primary goal is
to assess the impact of endocytosis and intracellular traf-
ficking on drug distribution. The tissue is modeled as a
continuum. The various chemical species (e.g., cell surface
receptors, intracellular ligand, etc.) in the tissue are modeled
as spatially continuous variables; discrete cells are not ex-
plicitly considered. Rather, each cell-associated species is
treated as a continuous variable in space, but is spatially
immobile. Only unbound extracellular drug is free to dif-
fuse. The discretization of the model for computer simula-
tion does, however, provide a spatial aspect to the cells as
described below. A schematic representation of the model
system is shown in Fig. 1. We impose cylindrical geometry
on the tissue, and the model is constrained to one dimen-
sion. Drug concentration in the blood plasma is time-depen-
dent. Access of drug to the tissue is governed by capillary
permeability. Extravascular drug diffuses away from the
capillary wall (r = 0) through the extracellular space (Fig.
1 a), and the model assumes that there is no flux of drug at
the boundary r = R. Drug binds to cell surface receptors and
may be internalized, recycled to the cell surface, and/or
released back into the extracellular space (Fig. 1 b). In the
general model, as indicated in Fig. 1 b, internalized drug and
receptors can be degraded in lysosomes, and the surface
apy of cancer (Pirker et al., 1985), delivery of drugs across
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receptor pool can be replenished by synthesis of new recep-
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FIGURE 1 Schematic representation of the cellular pharmacology
model. (a) Model geometry. The function Lp(t) is given by Eq. 7 and
represents the concentration of transferrin present in the blood plasma. The
flux of drug across the capillary wall is related to capillary permeability P
by Eq. 8. The drug may diffuse through the extracellular space of the tissue
with effective diffusion coefficient D, and may also interact with the cells
as shown in the inset. (b) Processes included in the general cellular
pharmacology model. Pentagons represent drug molecules. (c) Schematic
representation of a single CHO TfT1.1 1 cell and the specific transferrin/
CHO cell interactions included in the transferrin adaptation of the cellular
pharmacology model. The rate constants are defined in Table 1.
tors. However, these processes are not considered in this
work for reasons stated below. We omit nonspecific inter-
nalization of drug (fluid phase uptake), as it is considered
insignificant for extracellular drug concentrations <10-8 M
(Lauffenburger and Linderman, 1993). We illustrate con-
centration profiles for distances up to 1.0 mm from the
capillary wall. The very short distances (a few hundred
micrometers) may be relevant to established vascularized
tumors, whereas greater depths may be relevant for early
avascular tumors that can be several millimeters in diameter
before neovascularization occurs. Possible sinks such as
lymphatics are not considered in this initial study.
The cellular pharmacology model includes a reaction-
diffusion equation for extracellular ligand concentration
and a basic model for trafficking as described by
Lauffenburger and Linderman (1993). In this study, we
apply the general model to the specific system of trans-
ferrin and its receptor in the Chinese hamster ovary
mutant cell line TfT1.11 (Cain et al., 1991). Fig. 1 c is a
schematic representation of the endocytosis and traffick-
ing portion of the model that illustrates the application of
the cellular pharmacology model to the transferrin system
and TfT1.11 cells. We use aspects of a kinetic model of
the transferrin cycle proposed by Ciechanover et al.
(1983). Qualitatively similar models of the transferrin
cycle in human leukemic K562 cells and mouse terato-
carcinoma stem cells have been described (Klausner et
al., 1983; Karin and Mintz, 1981). Ciechanover et al.
(1983) based their model on experimental evidence in the
human hepatoma cell line HepG2 (Dautry-Varsat et al.,
1983) that transferrin and its receptor remain associated
during the endocytosis cycle, and no degradation of the
transferrin receptor occurs over short periods (hours).
The transferrin cycle model assumes that no synthesis of
new receptors occurs over similar time periods. Ciech-
anover et al. (1983) observed that endosomal receptor-
transferrin complexes contain apotransferrin, and surface
complexes contain either ferrotransferrin or apotrans-
ferrin. Trace amounts of iron in the surrounding medium
are sufficient to rapidly convert all apotransferrin to
ferrotransferrin as it dissociates from cell surfaces (Dau-
try-Varsat et al., 1983), and so all free transferrin is
considered to be ferrotransferrin. Throughout the paper,
we use the term transferrin as a catch-all term that is
inclusive of both transferrin species, but it is understood
that, unless otherwise specified, intracellular transferrin
is in apo form, extracellular transferrin is in diferric form,
and the surface pool of receptor/transferrin complexes
contains both diferric and apo forms. The dissociation of
ferrotransferrin and apotransferrin from surface receptors
is governed by distinct rate constants (Klausner et al.,
1983; Dautry-Varsat et al., 1983). Because the transferrin
receptor is considered to reside in coated pits whether
bound to ligand or not, there is no alteration of receptor
internalization rate resulting from ligand binding
(Lauffenburger and Linderman, 1993). We also incorpo-
rate experimental evidence (Cain et al., 1991) that
TfT1.11 cells have two recycle pathways that are distin-
guished by markedly different rates.
The equations that describe the cellular pharmacology
model as applied to the transferrin cycle in TfT1.11 cells are
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as follows. Extracellular transferrin concentration L (M) is
given by:
aL D( aL\\ nv
-=-t-tr-)JkfRsL-at -r ~ar ar)~ NAv
(1)
nv nv
+ kraCsa N + krdCsdN
~NAv dNA
The surface receptor complexes with diferric and apotrans-
ferrin, Csd (# cell-l) and Csa (# cell-), respectively,
change with time as:
adt = kfRsL -krdCsd-keRCsd (2)
atSa =
_kraCsa + [krec,ff + krec,s(l -ff)]Ci - keRCsa (3)
Surface free receptors Rs (# cell-) change with time as:
aR8
aRt =-kfRsL + kraCsa + krdCsd -keRRs
+ [krec,ff + krec,s( -ff)]Ri (4)
The time rates of change of intracellular receptor/transferrin
complexes Ci (# cell-) and intracellular free receptors Ri
(# cell-) are:
adc = keR(Csa + Cs)- [kecff + krec s(l -ff)]Ci (5)at
aR=
at = ikeRRs - Ekrec,tff + krec,s(1 - ff)]R, (6)
Table 1 summarizes the definitions of variables and param-
eters and provides base case values for the kinetic rate
constants and other parameters associated with the model
equations. The k values represent specific rate constants: kf
(M-1 s-1) is the forward binding rate constant for cell
surface receptor/transferrin binding; krd (s-1) and kra (s-1)
are reverse binding rate constants for diferric and apotrans-
ferrin, respectively; keR (s-1) is the rate constant for inter-
nalization of both free surface receptors and surface recep-
tor/transferrin complexes; and krec,f (s1) and krec,s (s') are
the rate constants for the fast and slow recycle pathways,
respectively. nv (cell * 1-1) is the cell number density in the
tissue. NAV (mol-1) is Avogadro's number.ff is the fraction
of internalized receptor/transferrin complexes that is recy-
cled through the fast pathway. D (cm2. s-1) is the effective
diffusion coefficient.
We model the ferrotransferrin source in the plasma as
an intravenous bolus dose of drug. To simulate the serum
pharmacokinetics of known macromolecular therapeu-
tics, we chose parameters measured for the biexponential
decay of the plasma concentration of radiolabeled F(ab')2
in humans (Fujimori et al., 1989). IgG F(ab')2 is a gly-
coprotein similar in molecular weight to ferrotransferrin.
TABLE I Definition of variables and parameters with base
case parameter values used in the cellular pharmacology
model
Symbol Definition Value
Ci (M) Intracellular transferrin
C., (#-cell-') Surface receptor/apotransferrin
complexes
C,, (#'cellH-) Surface receptor/diferric transferrin
complexes
CZ (M) Spatially averaged intracellular
transferrin
D (cm2.s-1) Effective diffusion coefficient 2 X 10-8
ff Fraction of intemal receptors and 0.815*
complexes recycled in fast pathway
keR (s-1) Internalization rate constant 3.333 X 10-3*
kf (M-l s-1) Transferrin/receptor association rate 5 x 104t
constant
k,d (s1) Transferrin/receptor dissociation rate 1.667 X 10-3*
constant for diferric transferrin
kr (s-1) Transferrin/receptor dissociation rate 4.333 X 10-2*
constant for apotransferrin
kf (s-1) Fast recycle pathway rate constant 1.359 X 10-3*
k,. (s-1) Slow recycle pathway rate constant 9.62 X 10-5*
L (M) Extracellular transferrin
L (M) Spatially averaged extracellular
transferrin
L (M) Initial plasma transferrin concentration 2.0 x 10-8
LP (M) Plasma transferrin concentration
NAV (molF) Avogadro's number 6.022 X 1023
n., (cell l-l) Cell number density 1.0 x 1012
P (cms- 1) Transferrin capillary permeability 9.0 X 10-7§
R; (#cell-1) Intracellular free receptors
RS (#-cell-') Surface free receptors
RT (#ce1l-) Receptor density 1.6 X 105
Tft a (M) Total cell-associated transferrin
Tftot (M) Total tissue transferrin
Tft1t (M) Spatially averaged total tissue transferrin
a1 Pharmacokinetic pre-exponential factor 0.6111
a2 Pharmacokinetic pre-exponential factor 0.391
A1 (s-1) Pharmacokinetic time constant 1.5 X 10-411
A2 (s-1) Pharmacokinetic time constant 6.3 x 10- 611
* Data for 33°C; Cain et al., 1991; * Ciechanover et al., 1983; § Baxter et
al., 1992; 11 Fujimori et al., 1989; ' Klausner et al., 1984.
The equation for the plasma ferrotransferrin concentra-
tion Lp is:
Lp = Lo{a, exp(-Alt) + a2 exp(-A2t)}
where a,, A1, a2, and A2 are fitted constants (Table 1), and
Lo is defined as a typical initial bolus intravenous dose. We
require two boundary conditions and the initial condition to
specify the transferrin system application of our model.
Transferrin flux from the capillary into the tissue is related
to capillary permeability and the transferrin gradient across
the capillary wall:
aL
-D-- =PL-DrOar r0 (p-Lr0 (8)
where P (cm - s-1) is the capillary permeability coefficient.
We assume no flux of transferrin at r = R due to symmetry
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with tissue surrounding adjacent capillaries, and thus the
second boundary condition is:
aL
ar
=0 at r= R (9)
Initially, there is no transferrin in the tissue and for all r:
L(r, 0) = 0
Ci(r, 0) = 0
C,a(r, 0) = 0 (10a-d)
C.d(r, 0) = 0
Ciechanover et al. (1983) determined that HepG2 cells
expressed only one-third of their total receptors on the
surface and kept two-thirds in intracellular locations, so we
specify the initial condition for R. and Ri as:
Rs(r, 0) = 0.333RT
(lOe-f)
Ri(r, 0) = 0.667RT
where RT (# cell-) is the total number of transferrin
receptors.
The model equations were made dimensionless with ap-
propriate scaling to identify groups of parameters that have
similar effects. The results are presented in dimensional
form, however, to provide a meaningful spatiotemporal
context. The results of parameter variation are organized in
sections representative of given dimensionless groups. Pa-
rameter variations were performed with constant affinity,
i.e., kra = krd, as explained in the Results section.
The volume that cells occupy is not obvious in the con-
tinuous equations above (Eqs. 2-6). The discretized equa-
tions for numerical simulation, however, have a spatial step
size of 10 ,um, on the order of a cell diameter. In this
discrete sense, each cell layer is 10 ,um thick and consists of
an extracellular space and a cellular compartment to which
ligands can bind and be internalized and recycled. Extracel-
lular ligand is exchanged between the extracellular com-
partments of adjacent cell layers via diffusive flux, and
cell-associated ligand can dissociate from a cell into the
extracellular compartment surrounding that cell.
Diffusion-only model
We modeled tissue transferrin distribution resulting from
diffusive transport alone using Eq. 1 with the same bound-
ary conditions and initial condition. For this case, kf, kra, and
krd were set equal to zero.
Diffusion-with-surface-binding model
We considered the effect of transferrin binding to cell
surface receptors without inclusion of cell trafficking rate
processes by solving the cellular pharmacology model with
the following changes. keR was set equal to 0. We chose a
receptor density RT (# * cell-) of 40,000, the steady state
value of RS observed in base case simulations of the cellular
pharmacology model. For the transferrin base case, we
required 69% of the surface transferrin to dissociate from
receptor as apotransferrin with rate constant kra, while the
remaining 31% dissociated as ferrotransferrin with krd. (An
analysis of the actual binding and internalization rate con-
stants shows that, if internalization and recycle are consid-
ered, 69% of initially surface-bound ferrotransferrin is in-
ternalized before it can dissociate from surface receptors,
and thus that percent dissociates as apotransferrin with kra
while the remaining 31% dissociates with krd. This has been
demonstrated experimentally in HepG2 cells (Ciechanover
et al., 1983).) To generalize the comparison among models,
the diffusion-with-binding case was also simulated with
constant affinity (kra = krd) for both normal diferric trans-
ferrin/receptor affinity (3 X 107 M-1, referred to as the
constant affinity base case) and higher affinity (109 M-1).
These simulations were compared with analogous cellular
pharmacology simulations.
Other calculated quantities
Extracellular and intracellular transferrin concentrations
were calculated as functions of time and space. Total tissue
transfemfin (apo plus ferro) concentration is a sum of intra-
cellular, surface-bound, and extracellular transferrin:
Tftot = L + Csa + Csd + Ci (11)
Total cell-associated transferrin (apo plus ferro) concentra-
tion is the sum of intracellular and cell surface transferrin
concentrations:
Tfa = Csa + Csd + Ci (12)
Additionally, the spatially averaged total, intracellular, and
extracellular transferrin concentrations were calculated as
the arithmetic averages of these concentrations to a distance
of 3 mm from the capillary wall and are denoted Tft.t, Ci,
and L, respectively.
Numerical solution method
Eqs. 1-10 were dedimensionalized and integrated numeri-
cally to calculate the distribution of extracellular and cell-
associated transferrin throughout the tissue for up to 96 h. A
fourth-order Runge-Kutta method (Press et al., 1989) was
used to integrate the kinetic balance equations (Eqs. 2-6).
Calculation of the spatial profile from Eq. 1 at each time
was simplified by offsetting the time step for this equation
by one-half time step from that of Eqs. 2-6. This makes Eq.
1 linear, because all variables except L are treated as con-
stants equal to the values calculated from Eqs. 2-6 at the
previous half time step. The Crank-Nicholson scheme
(Davis, 1984) was used to obtain the spatial solution for L
from Eq. 1 at each time step. All calculations were per-
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formed in double precision using FORTRAN 77 on a
Hewlett Packard (Palo Alto, CA) 9000 series Apollo 720
workstation. Spatial and temporal step sizes were 0.001 cm
and 25 s, respectively. No improvement of resolution was
achieved for smaller step sizes. The maximum radius of
tissue simulated was 3 mm.
Parameter values
Table 1 contains the parameter values used for the trans-
ferrin base case calculation. These values are used through-
out except where changes are noted. The binding and inter-
nalization rate constants were taken from experimental
literature for the transferrin cycle in HepG2 cells
(Ciechanover et al., 1983). The recycling rate constants are
for CHO TfT1.11 cells at 33°C and were taken from Cain
et al. (1991). The receptor density is that of wild-type CHO
as well as TfT1.11 at 33°C and was taken from Klausner et
al. (1984). The pharmacokinetic rate constants for drug
degradation in the plasma were taken from Fujimori et al.
(1989) as explained with Eq. 7. D, the effective diffusion
coefficient, was estimated by determining the scaling factor
for diffusion of transferrin and IgG in dilute solution using
a relation for dilute solution diffusivity (McCabe et al.,
1985). We assumed that the scale factor applies in tissue as
well as dilute solution, and scaled a value ofD measured for
IgG in tumors (Jain, 1990). The cell number density, nv, was
estimated to be 1012 cells * 1-1, a typical tissue cell density.
Capillary permeability, P, was assumed to be similar to that
for F(ab')2 and was taken from Baxter et al. (1992). A
reasonable therapeutic peptide concentration was chosen for
Lo, the initial plasma concentration of transferrin.
RESULTS
Base case calculations
The cellular pharmacology model (Eqs. 1-10) was simu-
lated with the base case parameter values for transferrin
given in Table 1. Spatial profiles of extracellular (L) and
intracellular (Ci) transferrin concentrations at 48 and 96 h
are plotted in Fig. 2. Both panels indicate that broadening
and flattening of the transferrin profile occur over time.
After very early times (minutes), intracellular transferrin
concentrations are higher than extracellular transferrin con-
centrations throughout the tissue as shown here, illustrating
a substantial retention of ligand by the cells.
We investigated whether including cellular pharmacol-
ogy affected the transferrin distribution by comparing the
cellular pharmacology model to models that considered
only diffusion of transferrin in the extracellular space (dif-
fusion-only model) or diffusion with reversible binding to
cell surface receptors (diffusion-with-binding model). Fig. 3 a
gives the spatial distribution of total transferrin Tftot for each
model at 48 h. Transferrin/cell interactions clearly affect the
amplitude of the total transferrin profile. The cellular phar-
macology model predicts a dramatic increase in amplitude
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FIGURE 2 Results of base case simulations for the cellular pharmacol-
ogy model. Spatial distribution of (a) extracellular transferrin L and (b)
intracellular transferrin Ci at 48 h and 96 h. Parameter values are given in
Table 1.
in comparison with the diffusion-only case, whereas the
diffusion-with-binding model predicts only a slight increase
in amplitude for the same parameter set. Also, the addition
of rate processes associated with transferrin internalization
and intracellular trafficking results in reduced penetration of
transferrin into the tissue. Fig. 3 b shows the temporal
distribution of average total transferrin concentration Tftot
given by each of the three models. The cellular pharmacol-
ogy model gives the highest Tftot at all times, while the
diffusion-with-binding model has a Tftot profile that is very
similar to the diffusion-only model. Included on Fig. 3 b is
a plot of the average intracellular transferrin concentration
Ci as determined by the cellular pharmacology model. From
this curve, it is clear that much of the transferrin present in
the tissue at any given time is in the intracellular pool.
Because the diffusion-with-binding model does not account
for internalized transferrin, the uptake and retention of
transferrin are grossly underestimated by that model for
these parameter values.
The presence of cells also has a marked impact on the
distribution of free transferrin. Fig. 3 c gives the spatial
distribution of extracellular transferrin L for the three mod-
els at 48 h. At most points, the extracellular transferrin
concentration and penetration depth are largest for diffusion
.......
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FIGURE 3 Comparison of transferrin base case (a-c), constant affinity base case (d), and constant high affinity (e) simulations for the cellular
pharmacology, diffusion-with-binding, and diffusion-only models. Note that the ordinates have different scales. (a) Spatial distribution of total transferrin
Tftot (extracellular plus cell-associated) at 48 h. (b) Temporal distribution of spatially averaged total transferrin Tftot. Also shown is the temporal distribution
of average intracellular transferrin Ci calculated using the cellular pharmacology model. This illustrates that much of the transferrin is intracellular in the
cellular pharmacology model. Spatially averaged quantities represent the arithmetic average in a depth of tissue up to 3 mm from the source. (c) Spatial
distribution of extracellular transferrin L at 48 h. (d) Spatial distribution of total transferrin Tft.t at 48 h for KA = 3 X 107 M-1, which is the KAwhen the
reverse binding constant is the same for apo and diferric transferrin. (e) Spatial distribution of total transfefrin Tftot at 48 h for KA = 109 M-1 (kf = 105
M-' S- , kd = 10-4 s-1). The diffusion-only curve (solid line) is the same as in d.
alone, and nearly as great for diffusion with surface binding.
However, though the amplitude of L is unchanged, the
penetration depth is greatly reduced when cellular pharma-
cology is considered. Consideration of Fig. 3, a-c, reveals
that the penetration ability of transferrin is compromised by
the addition of rate processes associated with cells, and
inclusion of the detailed cell biology causes tissue retention
and uptake of transferrin that are much greater than pre-
dicted by diffusion with surface binding alone.
It is important to note that in the transferrin cycle the
transition from diferric to apotransferrin during internaliza-
tion and recycle causes a shift from a slower to a faster rate
of dissociation of transferrin from the cell surface. Accord-
ingly, both the cellular pharmacology and diffusion-with-
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binding results are more similar to the diffusion-only results
than if this transition did not occur. This is because the fast
dissociation of apotransferrin from the cell reduces the time
transferrin is retained by a cell once bound (diffusion-with-
binding model) or bound, internalized, and recycled (cellu-
lar pharmacology model). (Recall that the diffusion-with-
binding case was calculated using the surface receptor
number and dissociation rates experienced in the cellular
pharmacology base case to allow a direct comparison of the
models.) When the affinity is held constant, i.e., when kra =
krd, there is a greater distinction between the diffusion-with-
binding case and diffusion alone. Fig. 3, d and e give the
spatial distribution of total transferrin for the three models
with KA = 3 X 107 M-1 and 109 M-1, respectively. The
higher affinity might represent that of an antibody for its
antigen. These panels show that both the cellular pharma-
cology and diffusion-with-binding models give higher peak
transferrin concentrations and reduced penetration as affin-
ity increases. However, the cellular pharmacology model
still predicts the highest transferrin concentration at small r
as well as the greatest reduction of penetration.
Parameter sensitivity analysis
In the study of parameter variation described below, we set
kra = krd = 1.667 X 10-3 S-1 for all cases unless otherwise
specified. This was necessary to observe the effects of the
specific parameter variations listed without also varying the
fraction of transferrin dissociating with the rate constants kra
and krd.
Effects of diffusion coefficient (D) and initial drug
concentration (Lo)
Increasing Lo greatly increases the amplitude of the total
transferrin (Tftot) profile in the tissue while the depth of
penetration is relatively unaffected (Fig. 4a). This occurs
because Lo only multiplies temporal terms in Eq. 1, as well
as scales the plasma concentration and capillary wall bound-
ary condition. Conversely, increasing D results in a dra-
matic broadening and flattening of the total transferrin pro-
file (Fig. 4 b). Increasing the value of the effective
diffusivity represents either a molecule of smaller molecular
weight or a tissue with less resistance to diffusion. Because
the capillary permeability is not also changed to reflect
alterations in molecular weight for these calculations, the
plots in Fig. 4 b illustrate the latter case. Thus, the decreas-
ing peak transferrin concentration and increasing tissue pen-
etration associated with increasing diffusivity are caused by
faster diffusion away from the blood vessel once the drug
escapes the vessel. The results shown in Fig. 4 indicate that
raising dosage (LO) can affect tissue concentration but not
depth of penetration under nonsaturating conditions. How-
ever, if effective diffusivity can be modified, the penetration
depth of drug can be directly modulated. The effects of
these parameters on intracellular transferrin concentration
Ci and extracellular transferrin concentration L are similar
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FIGURE 4 Effects of initial plasma transferrin concentration Lo and
effective diffusion coefficient D on spatial distribution of total transferrin
Tftot. (a) Dependence on Lo: Lo = 4 x 10-9, 2 X 10-8 (base case), and
10-7 M. (b) Dependence on D: D = 4 x 10-9, 2 X 10-8 (base case),
and 10-7 cm2 S-1. Simulation time was 48 h. Similar trends are seen for
all times compared up to 96 h.
to those for total transferrin concentration Tftot and hence
are not shown.
Effects of recycling parameters (ff, krec f, krc s)
We considered the impact of the recycling parameters if,
krec,f, and krec,s on the distribution of transferrin in the tissue.
These parameters are grouped together in Eqs. 3-6, so
varying any one is identical to varying the others propor-
tionally. The effects are illustrated by varying krecf. A
fivefold increase or decrease of krec,f from the base case
value has negligible effects on both extracellular transferrin
concentration L (Fig. 5, solid curves) and total transferrin
concentration Tft.t (Fig. 5, dotted curves). However, the
intracellular concentration Ci (Fig. 5, dashed curves) de-
creases significantly as krec,f increases. This occurs because
increasing krec,f, krec,s, or ff effectively decreases transferrin
cycle time, the time it takes for a transferrin molecule to
traverse the entire internalization and recycling pathway.
Hence, once internalized, a transferrin molecule is recycled
more quickly to the cell surface for larger krecf. The cell
surface transferrin pool is simultaneously replenished, re-
sulting in a nearly constant total cell-associated pool (not
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FIGURE 5 Effects of fast recycle rate constant krec
of Tf,0,, L, and Ci at 48 h for krec f = 3.333 X 10-4,
case), and 8.335 X 10-3 s-1. Both total and extraci
dence on kre,f are given by sets of indistinguishabl(
solid curves, respectively).
shown). Thus, the only effect of varying i
swap drug between cell surface and intrac
Effects of internalization parameter (keR)
The effects of varying keR (internalization
receptor/transferrin complexes and free sl
for the constant affinity system are shown
the effects of krec,f (Fig. 5), a 25-fold variat
appreciable effect on either the total (TftAt
curves) or extracellular (L, Fig. 6 a, solid cl
profiles. In contrast, intracellular transfen
(Ci, Fig. 6 a, dashed curves) increases with increasing keR at
all exposed r, while it decreases for the same variation of
ellular Tf krec,f. Although increasing either parameter decreases the
cycle time for a ligand, increasing keR also increases the
likelihood that surface-bound transferrin will be internalized
before it can dissociate and diffuse away (the rate of inter-
nalization is keR (Csa + C5d) while the rate of dissociation is
krd (Csa + Csd)). For the keR range studied (keR = 6.667 X
10-4 S-1 to 1.667 X 10-2 S-1, with krd = 1.667 X 10-3
s-1), this latter effect overwhelms the change in cycle time
and results in the larger internal pool for larger keR.
0.8 1.0 This result is observed for the constant affinity case
primarily because bound ligands are reinternalized and tra-
f. Spatial distribution verse the endocytic cycle several times before dissociation
1.667 X 10-3 (base from the cell. In contrast, the variable affinity condition
ellular profile depen- (kra > krd, the "true" transferrin system) causes nearly all
e curves (dotted and apotransferrin to dissociate from the cell after one cycle,
leaving little to be reinternalized. Because of this, varying
keR has quite different effects in the variable affinity con-
recycle rate is to dition than in the more general constant affinity case de-
ellular pools. scribed above (Fig. 6a). This is the only parameter that has
a qualitatively different effect for the two conditions. The
effects of keR for variable affinity conditions (kra > krd) are
illustrated in Fig. 6, b-d. As keR increases, the amplitude of
rate constant for total transferrin concentration (Tft0t) decreases while pene-
urface receptors) tration depth increases (Fig. 6 b, dotted curves). Simulta-
in Fig. 6 a. Like neously, the penetration depth of extracellular transferrin L
tion of keR has no increases (Fig. 6 b, solid curves). Recall that Tftot and L are
, Fig. 6 a, dotted largely unaffected by changes in keR when affinity is con-
urves) transferrin stant (Fig. 6 a). An additional change is that the effect of
rin concentration increasing keR on intracellular transferrin (Ci) is biphasic
FIGURE 6 Effects of varying the
internalization rate constant keR for
(a) the constant affinity condition (kra
= krd =1.667 X 10-3 s-1) and (b-)
the true transferrin case which has
variable affmity (kra > krd). The val-
ues of keR used for the simulations in
all panels are 6.667 X 10-4, 3.333 X
10-3 (base case), and 1.667 X 10-2
s -, as indicated in the panels. Re-
sults are at 48 h. (a) Constant affinity
condition. Spatial distributions of to-
tal tissue transferrin (Tftot), extracel-
lular transferrin (L), and intracellular
transferrin (Ci) concentrations. Vary-
ing keR has little effect on Tftot and L,
which are given by sets of indistin-
guishable curves (dotted and solid
curves, respectively). (b-d) True
transferrin (variable affinity) condi-
tion. Spatial distributions of (b) Tftot
(dotted curves) and L (solid curves),
(c) Ci, and (d) cell surface transferrin
(Csa + C,d) concentrations. The dif-
ferences between the constant affin-
ity and variable affinity cases are dis-
cussed in the text.
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(Fig. 6 c), with an optimum intracellular distribution occur-
ring when the base case value of keR is used. Increasing or
decreasing keR causes a loss of amplitude or penetration
depth, respectively. These results are caused by the combi-
nation of several cellular changes. First, the overall likeli-
hood of internalization is decreased in comparison with the
constant affinity case, because the net rate of transferrin
dissociation (which now equals krd CSd + kra Csa; kra > krd)
is now much faster than the rate of internalization (keR
(Csd + Csa)); bound transferrin cycles through the cell only
once before fast dissociation as apotransferrin. This is true
for the entire range of keR studied, because keR is much
smaller than kra. Second, in the variable affinity case, in-
creasing keR shortens the cycle time at both the internaliza-
tion step and the dissociation step (because of the diferric to
apotransferrin transition that occurs during recycle). Third,
there is a shift of free receptors from the surface to inside
the cell as keR increases. This reduces the ability of the cell
to capture free extracellular transferrin, resulting in a large
decrease in cell surface complexes with increasing keR (Fig.
6 d). The biphasic variation in intracellular concentration
with keR (Fig. 6 c) is the result of a tradeoff between the
changes in cycle time and internalizable surface complex
concentration described above. Extracellular transferrin
penetrates to greater depths with increasing keR because less
is captured by the cells, owing to fewer cell surface recep-
tors (Fig. 6 b). The sum of the effects on the intracellular,
cell surface, and extracellular pools results in increased
penetration but decreased maximum amplitude in the total
tissue transferrin profile (Fig. 6 b).
Effects of binding parameters (kf, krd)
The effects of binding rates on the distribution of transferrin
in tissue were examined by varying the binding rate param-
eters kf and krd. The effects of kf on total (Tft.t), intracellular
(Ci), and extracellular (L) transferrin concentrations at 48 h
are plotted versus distance in Fig. 7. Tft.t and Ci increase
dramatically in amplitude but decrease in penetration depth
(Fig. 7, a and b) with increasing kf. In contrast, L profiles
(Fig. 7 c) show decreasing penetration depth without appre-
ciable change in maximal amplitude as kf increases (note
differences in scale on the ordinates). This result occurs
because faster binding (kf increasing) with subsequent in-
ternalization causes more cell-associated transferrin and
creates a larger intracellular transferrin pool while depleting
the extracellular pool. This is further illustrated by the effect
of kf on the partitioning of transferrin among intracellular
(Ci), extracellular (L), and total cell-associated (Tftca) pools
(Fig. 8). Fig. 8 a shows that when kf is low (104 M-1 S-1)
much of the transferrin in the tissue is extracellular. How-
ever, when kf is high (2.5 x 105 M-1 s-1), most of the
transferrin is intracellular (Fig. 8 b) (note differences in
scale on the ordinates). A striking difference between the
two panels is that the penetration of transferrin is much
greater for low kf than for high kf. Because cells retain
higher intracellular concentrations of transferrin as kf in-
25.0
20.0
2
C 15.0
10.0_ I-
51.0
0.0 .
0.0
20.0
j 15.0r
C
10.0
=
Cu
c 5.0L
0.0
0.0
0.8
0.7
O 0.6
C
-X 0.5
L-
0 0.3
w 0.2
0.1
0.0
0.2 0.4 0.6
Distance (mm)
0.2 0.4 0.6
Distance (mm)
0.0 0.2 0.4 0.6
Distance (mm)
0.8 1.0
0.8 1.0
0.8 1.0
FIGURE 7 Effects of forward binding rate constant kf. Dependence of
spatial distribution of (a) total transfernin Tft.,, (b) intracellular transferrin
Ci, and (c) extracellular transferrin L at 48 h; kf = 104, 5X 104 (base case),
and 2.5 x O5M` s-.
creases, the cell plasma membrane represents a physical
barrier to transferrin penetration into the tissue. We refer to
this phenomenon as "internal trapping."
The effects of krd are similar (although opposite in direc-
tion) to those presented for kf in Figs. 7 and 8, and so the
simulations are not shown. The effects of binding parame-
ters are often analyzed in terms of the affinity constant KA,
the ratio of forward and reverse binding rate constants.
Clearly, the effects of affinity on transferrin distribution in
tissue are implied by the effects of kf just discussed and
were also shown in Fig. 3, d and e. In this study, the
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FIGURE 8 Effect of forward binding rate constant
transferrin among extracellular (L), intracellular (C1)
ciated (lftca) pools. Recall that TAca is the sum of intra
bound transferrin. Spatial distributions at 48 h are sh
M-1 s-' and (b) kf = 2.5 X 105 M-1 s-'. Note the d
ordinates of (a) and (b). This result demonstrates that c
of transferrin is caused by the internalization of tranm
maximum free transferrin concentration ol
X 10-9 M; data not shown) is lower than
constant KD (=1/KA), illustrating that we
unsaturated conditions in all cases.
Effects of receptor density parameters (RT,
Receptor density can be modified either
total number of receptors per cell (RT) or
density (nj), although the latter might also a
diffusion coefficient. Average total, intrace
cellular transferrin concentrations all dep
density and closely parallel the behavior sh4
of affinity described above, and hence the
not shown. At all times, the dependence ol
concentration Tftot on receptor density is siI
for intracellular transferrin concentration (
ceptor density results in an increased ampli
C1 that coincides with reduced penetration
ison of partitioning of transferrin among:
tracellular, and total cell-associated pools I
density and low receptor density demonsti
trapping phenomenon as illustrated in Fig. 8 for variations
in kf. This occurs because increased receptor density results
in greater capture of transferrin and leads to decreased
penetration of extracellular transferrin in conjunction with
greatly increased amplitude of intracellular transferrin con-
centration Ci.
DISCUSSION
We have developed a mathematical model for the transport
0.8 1.0 and distribution of macromolecular drugs in physiological
tissues. The model, referred to as the cellular pharmacology
,
:
. . . Jmodel, includes diffusion of drug in the extracellular space,
reversible binding of drug to cell surface receptors, and
internalization and intracellular trafficking of drug by cells.
This detailed consideration of cellular pharmacology distin-
guishes our model from previous models that either ne-
glected cellular internalization and routing of drug or
lumped these processes and described them with a single
rate constant. In this paper, we present results for the dis-
tribution of transferrin in a tissue expressing the transferrin
receptor. However, the model is easily applied to any drug/
. . receptor system or tissue type for which the required pa-
0.8 1.0 rameter values are known. Note that all parameter values
used in these simulations are for native transferrin as the
ligand. Clearly, rate constants might be different for trans-
kf on partitioning of ferrin conjugated to a therapeutic agent.
i, and total cell-asso- The effectiveness of targeted therapeutic agent depends
acellular and surface-
own for (a) kf = 104 on both its potency and its access to the tissue of interest. In
lifferent scales on the addition, cellular interactions with a targeting drug greatly
Jecreased penetration influence drug potency. There is abundant evidence that the
sferrin. strength of drugs such as immunotoxins containing protein-
synthesis inhibitors or oligonucleotides for gene therapy is
related to the respective rates of internalization and degra-
served (L = 4.6 dation of these drugs (Byers et al., 1991; Wargalla and
the dissociation Reisfeld, 1989) as well as to the particular intracellular
have considered routing pathway through which they are directed (May et
al., 1991; Chignola et al., 1990). Further, Mattes et al.
(1994) have recently suggested that internalization of radio-
ni labeled antibodies may improve the cytotoxicity of these
v~) drugs if the radioisotopes are retained within cells. There is
by changing the no consensus, however, as to which cellular drug processing
the cell number step is most important in determining therapeutic effect.
alter the effective Clearly, drug delivery strategies must be designed to opti-
llular, and extra- mize cellular behavior based on the therapeutic goal, e.g.,
)end on receptor cell toxicity versus gene therapy. While drug/cell interac-
own for variation tions are critical to drug potency, these same processes may
simulations are also affect drug access to the tissue of interest. For example,
f total transferrin immunotoxins have been observed to distribute nonuni-
milar to that seen formly in vitro (Sutherland et al., 1987; Kikuchi et al., 1992)
Increasing re- and in vivo (Juweid et al., 1992; Sung et al., 1993). To
itude of Tftot and explain this nonuniformity, mathematical analyses of the
depth. Compar- distribution of macromolecular drugs have identified con-
intracellular, ex- tributing factors such as interstitial pressure gradients (Bax-
for high receptor ter and Jain, 1991) and the "binding site barrier" (van Osdol
rates the internal et al., 1991). However, these models also implied that the
k= 104 M-1s1
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I.. /lntracellular Tf
Extracellular Tf
I.
l . 7 " |
kf =2.5x105M-1s-1
Total cell-associated Tf
i, Intracellular Tf
.,
Extracellular Tf
D */X.__ ,~~~. I.
~ ~ ~
.II
Rippley and Stokes 835
Volume 69 September 1995
heterogeneity of the spatial distribution of drug would be
increased by drug interactions with cells.
We developed the cellular pharmacology model to test
the hypothesis that cellular processing of a drug influences
its distribution in a tissue. We compared the distribution of
transferrin predicted by the cellular pharmacology model
with those predicted by simpler models that considered
either extracellular diffusion of transferrin alone, or extra-
cellular diffusion and reversible binding of transferrin to
cell surface receptors. The results show that the penetration
of transferrin is compromised by the addition of rate pro-
cesses associated with transferrin/cell interactions. The total
amount of transferrin in the tissue close to the source
increases, however, because much is internalized by the
cells. These results also demonstrate that models that do not
include intracellular trafficking greatly underestimate the
uptake and retention of drug in a tissue. To examine whether
the observed differences among models were significant for
different receptor/ligand affinities, we compared the distri-
bution of transferrin predicted by the three models for
constant diferric transferrin affinity (kra = krd = 1.667 X
10-3 s-1) to that given by a higher, antibody-like affinity
(Fig. 3, d and e). The results show that the differences
between the cellular pharmacology model and the diffusion
with binding model are applicable to and exaggerated for
higher affinity receptor/ligand systems.
The cellular pharmacology model provides an initial
evaluation of the potential effects of cellular pharmacology
on drug distribution in a tissue where diffusive transport
occurs, and it has some limitations. The tissue is modeled as
a homogeneous continuum, and an effective diffusion co-
efficient is used to account for the tissue porosity and
architecture. Additional means of transport such as convec-
tion, intracellular diffusion, and directed vesicular transport
within cells have been neglected, but may be important in
certain tissue types. We have also neglected the possibility
of extracellular sinks for drug such as degradation, lym-
phatic uptake, and nonspecific binding to extracellular ma-
trix elements. On the other hand, we have found that the
results presented here, in terms of the effects of cellular
pharmacology on drug transport, are qualitatively the same
for a number of different boundary conditions (constant
drug concentration at r = 0, time-dependent drug concen-
tration at r = 0 as reported here, varying capillary perme-
ability, no drug at r = oo) and tissue geometries (planar,
cylindrical) (results not shown).
We have examined the sensitivity of the cellular pharma-
cology model results to key parameters to investigate how
one might try to modulate drug delivery by modifying
cell/drug interactions. Our analyses indicate that increasing
dosage (Lo) can affect tissue concentration of drug but not
depth of penetration under nonsaturating conditions. In con-
trast, penetration depth of drug can be directly modulated by
modifying the effective diffusivity. We also find that vary-
ing the binding and trafficking rate parameters affects sev-
eral cell characteristics including cell surface receptor num-
endocytic cycle time. Results of variation of recycling and
internalization parameters (krecf, krec,s, if, and keR) illustrate
that one might dramatically alter the intracellular exposure
to drug without significantly affecting the total or extracel-
lular drug distribution. These results indicate that modifying
the recycling and internalization parameters may influence
the efficacy of drugs that must act intracellularly. Changes
in binding parameters that mimic an increase in affinity
(e.g., increasing kf or decreasing krd) or, alternatively, in-
creases in receptor density via RT or nv, cause a pronounced
translocation of transferrin from outside cells to mostly
inside cells; this leads to a reduction of transferrin penetra-
tion into the tissue. Thus, there may be a trade-off between
homogeneity of drug distribution and intracellular exposure
to drug.
An important aspect of the transferrin cycle is the tran-
sition of transferrin from the diferric state to the apo state as
a result of internalization and recycle. This transition causes
a large fraction of the cell-associated transferrin (that which
is internalized and recycled) to dissociate from receptors at
an increased rate versus diferric transferrin. Although this
phenomenon is essential to an accurate model of the trans-
ferrin cycle, its inclusion in our model introduces ambiguity
in the interpretation of the results of parameter sensitivity
analyses, as it is not possible to vary most parameters
without also varying the fraction of transferrin dissociating
with kra compared with krd. For this reason, we performed
all parameter variations with kra = krd (Figs. 4-8). This
modification both ensures the clarity of interpretation of our
results and helps to generalize the cellular pharmacology
model results to ligands other than transferrin. The results
calculated with constant affinity (Figs. 3, d and e, and 4-8)
illustrate that the influence of cellular pharmacology is not
limited to the transferrin system but is a phenomenon com-
mon to systems in which receptors and receptor/ligand
complexes are internalized. The true transferrin system
(kra > krd) approximates the case in which receptor and
ligand dissociate in the endosome and recycled free ligand
returns directly to the extracellular space, while the kra = krd
system represents the case in which receptor and ligand
remain associated in the endosome and recycled ligand
undergoes a membrane dissociation event before returning
to the extracellular space. It was noteworthy to find that the
results for the true transferrin system were qualitatively the
same as the kra = krd results for variation of all parameters
except keR. This finding illustrates the broad applicability of
the results presented here. Another aspect of the model
specific to the transferrin system is the slow recycle path-
way. This pathway contributes very little to the retention of
transferrin by cells for the value of krec,s used, however, and
there would be no significant change in the results if the
slow pathway were not included (results not shown).
The cellular pharmacology model provides a distribution
of intracellular drug concentration, an important piece of
information that is lacking in other drug distribution mod-
els. Interestingly, the cellular pharmacology model predicts
ber, likelihood of internalization of bound ligand, and
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that most of the transferrin present in the model tissue after
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very early times is intracellular and thus unable to penetrate
to greater tissue depths. This indicates that the observed
nonuniform distributions of targeting drugs may be caused
mainly by intracellular containment, or "internal trapping."
In contrast, the diffusion-with-surface-binding model pre-
dicts that penetration of drug is impeded because of specific
binding of drug to cell surface receptors. This result was
described as a binding site barrier by Fujimori et al. (1989).
Experimental support for the binding site barrier hypothesis
was provided by Juweid et al. (1992), who observed that
heterogeneous distribution of monoclonal antibodies in
guinea pig carcinomas corresponded to antigen location.
These investigators inferred that a binding site barrier was
responsible for low antibody penetration. Pervez et al.
(1988) and Shockley et al. (1992a) found similar behavior
of monoclonal antibodies in LoVo xenografts and human
melanoma xenografts, respectively. The above studies
clearly distinguished between extracellular antibody and
cell-associated antibody, but the distinction between sur-
face-bound antibody and intracellular antibody was either
not discernible or not investigated. The concept of internal
trapping of drug extends the binding site barrier theory;
because receptor-mediated internalization requires specific
binding of drug to cell surface receptors, the two are nec-
essarily related.
The internal trapping phenomenon is clearly illustrated
by the sensitivity of the cellular pharmacology model to
changes in receptor density and receptor/transferrin affinity.
Weinstein et al. (1987) and Fujimori et al. (1989) observed
in modeling studies that the barrier to drug penetration grew
in proportion to increases in these parameters. We observe
a similar result in that the distribution of transferrin through-
out the model tissue is increasingly nonuniform as receptor
density or receptor/transferrin affinity increases. However,
in our system, the reduced penetration of transferrin is a
result of the intracellular containment that follows surface
binding and not surface binding in and of itself. A key
contrast between the consequences of the binding site bar-
rier theory and the concept of internal trapping is the fol-
lowing. Out of the context of intracellular drug distribu-
tions, one might speculate that increased cell surface
retention of drug leads to less uniform drug distribution and
hence submaximal drug efficacy. Our results show that, for
drugs that require internalization for activity, parameter
changes that enhance intracellular drug retention while de-
creasing extracellular drug penetration may make positive
contributions to drug efficacy.
It is necessary to note that internalization alone of tar-
geted therapeutics is not a guarantee of drug efficacy. The
mechanisms of action of many drugs require access to the
cytosol or nucleus. Because the details of the intracellular
routing associated with drug action are often not well char-
acterized, we have not accounted for this aspect of drug
efficacy. Rather, we have examined the total internalization
of transferrin with the presumption that some fraction of the
We tested the sensitivity of the cellular pharmacology
model to parameters that control the rates of internalization
and intracellular routing of transferrin. The results show that
total drug content in a tissue is not a sufficient indicator of
therapeutic effect for drugs that require intracellular access
for activity. For instance, we observed that large changes in
the rate of recycle of transferrin and in the fraction of
transferrin recycled in the fast pathway had dramatic effects
on the intracellular transferrin concentration profiles but did
not significantly affect total transferrin concentration in the
tissue. Similar results were seen for variation of the inter-
nalization rate constant. Hence, it may be possible to opti-
mize the intracellular drug concentration without altering
the extracellular and total drug profiles simply by modulat-
ing cellular drug processing parameters. In addition, these
results show that total tissue drug content can be misleading
if the goal is to predict intracellular concentration response
to parameter changes by studying the response of total drug
concentration. The effects of cellular drug processing pa-
rameters on transferrin distribution indicate that maximal
tissue content may not reflect optimal effectiveness of treat-
ment. These results are important in light of the fact that
total tissue drug content is a commonly measured indicator
of the successful delivery, and hence efficacy, of targeted
drugs. Temporal profiles of average total drug concentration
in a tissue (Langmuir et al., 1992; Shockley et al., 1992b;
van Osdol et al., 1991) are used as measures of average
tissue exposure to drug, while spatial profiles of total drug
concentration (Sung et al., 1993; van Osdol et al., 1991;
Baxter et al., 1992) illustrate which areas of the tissue have
been exposed to the drug and the extent of the exposure.
However, as the cellular pharmacology model demon-
strates, important information about drug location with re-
spect to individual cells (e.g., intracellular versus extracel-
lular) is lost in a measure of total drug concentration.
Our results illustrate that specific transferrin/cell interac-
tions can have a significant impact on the distribution of
transferrin throughout a model tissue. From this specific
application, we can generalize and predict that cellular
pharmacology is likely to influence the distribution, and
hence efficacy, of any targeted drug. Models such as ours
that incorporate cellular pharmacology should be beneficial
in identifying key processes and rate-limiting steps that
govern drug distribution in a particular tissue, and hence can
be useful tools for the rational design of drugs. In addition,
such models can be used to provide detailed tissue-level
input to pharmacokinetic analyses of whole-body drug dis-
tribution. To these ends, future work needs to examine the
cellular pharmacology/transport behavior for different li-
gand/receptor systems (e.g., epidermal growth factor and its
receptor, anti-transferrin receptor antibody/transferrin re-
ceptor), different cell types, and different drug delivery
protocols (e.g., two-step antibody therapy) to determine the
impact of drug/cell interactions on the distribution of these
intracellular drug will have the desired effect.
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